Tapering or discontinuation of etanercept (DrugBank: Etanercept)
15 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
15 | Inclusion body myositis | 0 |
28 | Systemic amyloidosis | 0 |
35 | Pemphigus | 0 |
38 | Stevens-Johnson syndrome | 0 |
39 | Toxic epidermal necrolysis | 0 |
46 | Malignant rheumatoid arthritis | 0 |
50 | Dermatomyositis | 0 |
53 | Sjogren syndrome | 0 |
56 | Behcet disease | 0 |
60 | Aplastic anemia | 0 |
85 | Idiopathic interstitial pneumonia | 0 |
228 | Bronchiolitis obliterans | 0 |
271 | Ankylosing spondylitis | 1 |
285 | Fanconi anemia | 0 |
298 | Hereditary pancreatitis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03880968 (ClinicalTrials.gov) | March 1, 2012 | 12/3/2019 | Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis | Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis: a Prospective, Randomized Multicentric Study on Disease Activity Guided Etanercept Tapering or Discontinuation | Spondylitis, Ankylosing | Drug: tapering or discontinuation of etanercept | Second Affiliated Hospital, School of Medicine, Zhejiang University | Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine;First Affiliated Hospital of Wenzhou Medical University;The First Hospital of Jiaxing;Shaoxing Second Hospital;Shanghai Jiao Tong University Affiliated Sixth People's Hospital;Ningbo Medical Center Lihuili Hospital;Wenzhou Central Hospital;Zhejiang Provincial People's Hospital;Shaoxing People's Hospital | Completed | 18 Years | 65 Years | All | 311 | Phase 4 | NULL |